Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran dual therapy versus warfarin triple therapy after PCI in NVAF
NL-OMON44285Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dabigatran, warfarin, clopidogrel, ticagrelor and aspirin in Atrial fibrillation (AFib) and coronary arteriosclerosis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Primary safety endpoint. Started Feb 2015; status: active, not recruiting.
02
Drugs
dabigatranwarfarinclopidogrelticagreloraspirin
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON44285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44285.